NGM Bio
South San Francisco, US · Founded 2024 · 75 employees on LinkedIn · 2 known investors
NGM Bio is a biopharmaceutical company developing NGM120, a GDF15/GFRAL antagonist antibody, to treat conditions rooted in overactivation of the GDF15 pathway. Its current programs target hyperemesis gravidarum (extreme pregnancy sickness) and cancer cachexia, both in Phase 2 clinical trials.
Founders & leadership
DP
Diana Peng BockusExecutive
Board
TK
Tim KutzkeyBoard director
PS
RM
Roger M. PerlmutterBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$142M disclosed across 1 round · 2024
▶$142MraisedMar 2026 · 26 investors · BiotechnologyRule 506(b)
▶$142MraisedMar 2026 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Diana Peng BockusExecutive Officer, Director
- Tim KutzkeyDirector
- Roger M. PerlmutterDirector
- Peter SvennilsonDirector
- Offering amount
- $142M
- Amount sold
- $142M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapMNG Health7 shared keywordsProvider of technology-enabled multi-channel marketing solutions for pharma, biotech, and medical device brands.
Robinhood7 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Globaldata6 shared keywordsGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Companies competing with NGM Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does NGM Bio do?
- NGM Bio is a biopharmaceutical company developing NGM120, a GDF15/GFRAL antagonist antibody, to treat conditions rooted in overactivation of the GDF15 pathway. Its current programs target hyperemesis gravidarum (extreme pregnancy sickness) and cancer cachexia, both in Phase 2 clinical trials.
- Who are NGM Bio's investors?
- NGM Bio's investors include Rho Ventures, The Column Group.
- How much funding has NGM Bio raised?
- NGM Bio has disclosed $142M raised across 1 round.
- Where is NGM Bio headquartered?
- NGM Bio is headquartered in South San Francisco, US.